Search

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise period of the company's Series 4 warrants, 4.82 warrants were exercised, constituting 97% of the total amount of the warrants.

The total gross proceeds received by the Company from the exercise of the warrants is NIS 3.6 million.

Mr. Yossi Ben-Yosef, CEO of the company, said: "I see the 97% exercise rate of the warrants as a success, and thank the warrant-holder public for its vote of confidence in the company and in its potential."

© 2020 by Kadimastem

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon